Hims & Hers Health faces securities fraud class actions in the U.S. District Court for the Northern District of California over alleged misstatements and omissions involving consumer privacy, prescription billing, subscription cancellations and regulatory risks. Kaplan Fox & Kilsheimer LLP announced a case for investors who purchased or acquired HIMS securities from Aug. 4, 2025, through July 29, 2026, while Robbins Geller Rudman & Dowd LLP has separately publicized the matter identified as Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313 (N.D. Cal.). The complaints cite allegations by the Federal Trade Commission, the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection that Hims & Hers shared health information with third parties including Meta and Snap, charged consumers for prescriptions shortly after intake forms were submitted, and made cancellation and privacy practices difficult or misleading. Hims & Hers shares fell $4.32, or 14.73%, to $25.00 on July 29, 2026. Investors have until Nov. 2, 2026, to seek lead plaintiff status.